RFL On Other Exchanges

rafael holdings inc-class b (RFL) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

rafael holdings inc-class b (RFL) Related Businessweek News

No Related Businessweek News Found

rafael holdings inc-class b (RFL) Details

Rafael Holdings, Inc. holds commercial real estate assets. The company, through its subsidiaries, engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.

18 Employees
Last Reported Date: 10/15/18

rafael holdings inc-class b (RFL) Top Compensated Officers

Chairman & CEO
Total Annual Compensation: $252.1K
President & General Counsel
Total Annual Compensation: $272.3K
Chief Financial Officer
Total Annual Compensation: $98.3K
Compensation as of Fiscal Year 2018.
rafael holdings inc-class b
Rafael Pharmaceuticals Appoints Mona M. Wahba as Senior Vice President for Clinical Development and Operations

Rafael Pharmaceuticals, Inc. announced the appointment of Mona M. Wahba, MD, MSM, as Senior Vice President for Clinical Development and Clinical Operations. Prior to joining Rafael Pharmaceuticals, Dr. Wahba held executive positions in the pharmaceutical industry at both large and small companies, including Pfizer, Bristol-Myers Squibb, Novartis, Bayer, Taiho and Ipsen. She effectively created and led large teams and franchises for maximum performance, including joint ventures and alliances with different organizations.

Rafael Holdings, Inc. to Report Q2, 2019 Results on Mar 12, 2019

Rafael Holdings, Inc. announced that they will report Q2, 2019 results at 9:49 PM, GMT Standard Time on Mar 12, 2019

Rafael Holdings, Inc. Announces Devimistat (CPI-613®) to Be Explored in New Combination for T-Cell Lymphoma Treatment

Rafael Pharmaceuticals, Inc. announced that devimistat will be investigated in a new combination for the treatment of T-Cell Lymphoma under the ‘Tailoring CAR-based immunotherapy strategies to T-Cell Lymphoma’ project as a part of Stand Up To Cancer’s T-Cell Lymphoma Dream Team Research Grant. In addition to studying the new drug combination, investigators will perform sophisticated genetic tests to determine potential responders to the drug and whether this combination may be used prior to chimeric antigen receptor therapy (CAR-T) under the direction of Dr. Wei Zhang and Dr. Timothy Pardee.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

RFL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RFL.
View Industry Companies

Industry Analysis


Industry Average

Valuation RFL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 72.6x
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 64.9x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact RAFAEL HOLDINGS INC-CLASS B, please visit www.rafaelholdings.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.